Skip to main content
Smart Investors Daily
A

NYSE · A

Agilent Technologies, Inc.

Healthcare · Medical - Diagnostics & Research

$170.54

Up+$2.37 (+1.41%)

Updated Oct 10, 2026, 7:09 PM

SID Score

7.2/10

Composite research score

Smart Money

54/100

Neutral

Market cap
34.41B
P/E ratio
26.63
Dividend yield
0.73%
52-week range
$108.35 – $177.05
Volume
1.54M
Avg. volume
2.17M

Price performance · A

A price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

A closed at $170.54 after 21 trading sessions, up 16.07% for the selected period.

Last close
$170.54
Period change
+16.07%
Period low
$146.80
Period high
$175.21
Daily close
View OHLC price history
A OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$168.57$172.19$168.57$170.541.54M
Oct 8, 2026$167.48$168.66$163.32$168.172.72M
Oct 7, 2026$169.88$171.27$166.52$169.092.56M
Oct 6, 2026$172.77$176.38$168.01$169.331.87M
Oct 5, 2026$167.35$171.425$166.49$171.291.77M
Oct 2, 2026$168.25$170.24$166.33$167.782.29M
Oct 1, 2026$172.00$172.57$166.07$166.682.79M
Sep 30, 2026$174.44$176.04$172.27$172.312.59M
Sep 29, 2026$174.49$177.05$173.22$175.032.05M
Sep 28, 2026$170.00$176.0228$169.50$175.212.19M
Sep 25, 2026$171.98$172.94$169.43$172.792.58M
Sep 24, 2026$163.95$174.77$163.62$172.843.05M
Sep 23, 2026$166.54$168.94$163.27$165.323.24M
Sep 22, 2026$163.08$167.59$161.035$167.263.78M
Sep 21, 2026$157.87$162.89$157.08$161.942.71M
Sep 18, 2026$156.00$156.73$154.60$156.474.85M
Sep 17, 2026$156.00$156.89$154.03$156.342.89M
Sep 16, 2026$150.83$155.52$150.30$153.692.51M
Sep 15, 2026$147.00$150.96$147.00$150.271.68M
Sep 14, 2026$148.00$148.50$144.65$146.801.65M
Sep 11, 2026$144.48$146.975$143.18$146.931.78M

Latest A news

The latest Smart Investors Daily articles mentioning A.

A research

Overview

Company profile and research snapshot.

Company profile

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$165.56
Implied upside
—
Analysts
26
A recent ratings
DateFirmRatingTarget
Oct 7, 2026BarclaysOverweight—
Aug 27, 2026BernsteinOutperform—
Aug 27, 2026TD CowenBuy—
Aug 27, 2026JP MorganOverweight—
Aug 27, 2026Goldman SachsBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 1, 2026

Agilent Introduces the NovoStation Sample Preparation System for Automated Flow Cytometry Workflows

SANTA CLARA, Calif., October 01, 2026--Agilent Technologies Inc. (NYSE: A) today announced the launch of the NovoStation Sample Preparation System, a new automated platform designed to help laboratories simplify and streamline flow cytometry sample preparation. When paired with a NovoCyte flow cytometer and NovoExpress software, NovoStation offers an integration-ready solution that enables a hands-free sample-to-answer workflow, helping scientists spend less time preparing samples and more time

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.